Empliciti Injection, Powder, Lyophilized, For Solution
Product Images NDC 0003-4522

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Empliciti (NDC 0003-4522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Empliciti 300mg

Packaging label for EMPLICITI 300 mg per vial, elotuzumab injection powder, lyophilized for intravenous infusion. The label specifies reconstitution and dilution instructions, single-dose vial use, and storage conditions. Manufactured by Bristol-Myers Squibb Company, Princeton, NJ.*

FDA Label Image

Empliciti 400 mg Carton (Empliciti 400mg Carton)

Label for EMPLICITI (elotuzumab) injection, powder, lyophilized, for solution. The label indicates a 400 mg per vial strength for intravenous infusion only, manufactured by Bristol-Myers Squibb Company. The label includes instructions for reconstitution and storage, barcode, and regulatory information. The packaging is designed as a carton with text printed on multiple sides.*

FDA Label Image

Empliciti Figure 1 Prog Free Surv (Empliciti Fig1)

A Kaplan-Meier survival curve depicting progression-free survival rate (%) over time (months) for two groups labeled E-Ld and Ld. The graph shows the probability of progression-free survival decreasing over approximately 36 months, with E-Ld having higher survival probability than Ld. A hazard ratio with 95% confidence interval and p-value are displayed, alongside the number of subjects at risk at different time points for each group.*

FDA Label Image

Empliciti Fig2 S010

A Kaplan-Meier survival curve plot showing probability alive over time (months) for two groups labeled E-Ld and Ld. The chart includes hazard ratio (HR 0.82) with 95.4% confidence interval and a p-value of 0.0408. Below the graph, the number of subjects at risk for each group is displayed over time up to 84 months.*

FDA Label Image

Empliciti Fig3

A Kaplan-Meier plot showing progression-free survival probability over time (in months) for two groups: E-Pd (elotuzumab plus pomalidomide and dexamethasone) and Pd (pomalidomide and dexamethasone alone). The graph includes hazard ratio, confidence interval, and p-value, with risk table data indicating the number of subjects at risk at various time points.*

FDA Label Image

Empliciti Fig4 Os

A Kaplan-Meier survival curve illustrating overall survival (OS) over time in months. The chart shows two survival probability lines with corresponding subject risk data below the x-axis, comparing two groups labeled E-Pd and Pd. Hazard ratio (HR) with 95% confidence interval is noted below the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.